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Stroke has repercussions that extend beyond the suffering of
the patients and their families. It is the fourth leading cause of
death in the United States,1 imposing a formidable 74 billion
dollar ﬁnancial burden on the society in 2010.2 It is often
treatable especially when suspected early, and creativemeth-
ods of facilitating the diagnosis of stroke have shown effec-
tiveness. One such strategy is educating children about the
cardinal signs of stroke using hip hop, so that they can
recognize a stroke and initiate early medical evaluation
process.3 Although the incidence of stroke has followed a
downward trajectory in recent years in both Whites and
AfricanAmericans,4 approximately 795,000 stroke still occurs
each year. Of this, approximately 20 to 30% comprises of
carotid stenosis in its etiology,5,6 emphasizing the impor-
tance of effective treatment of carotid stenosis and the
secondary prevention of its recurrence.
The treatment of carotid stenosis centers on the following
three major modalities: medical management, carotid artery
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Abstract
The treatment of carotid stenosis entails three methodologies, namely, medical
management, carotid angioplasty and stenting (CAS), as well as carotid endarterectomy
(CEA). The North American Symptomatic Carotid Endarterectomy Trial (NASCET) and
European Carotid Surgery Trial (ECST) have shown that symptomatic carotid stenosis
greater than 70% is best treated with CEA. In asymptomatic patients with carotid
stenosis greater than 60%, CEA was more beneﬁcial than treatment with aspirin alone
according to the Asymptomatic Carotid Atherosclerosis (ACAS) and Asymptomatic
Carotid Stenosis Trial (ACST) trials. When CAS is compared with CEA, the CREST resulted
in similar rates of ipsilateral stroke and death rates regardless of symptoms. However,
CAS not only increased adverse effects in women, it also ampliﬁed stroke rates and
death in elderly patients compared with CEA. CAS can maximize its utility in treating
focal restenosis after CEA and patients with overwhelming cardiac risk or prior neck
irradiation. When performing CEA, using a patch was equated to a more durable result
than primary closure, whereas eversion technique is a new methodology deserving a
spotlight. Comparing the three major treatment strategies of carotid stenosis has
intrinsic drawbacks, as most trials are outdated and they vary in their premises,
deﬁnitions, and study designs. With the newly codiﬁed best medical management
including antiplatelet therapies with aspirin and clopidogrel, statin, antihypertensive
agents, strict diabetes control, smoking cessation, and life style change, the current
trials may demonstrate that asymptomatic carotid stenosis is best treated with best
medical therapy. The ongoing trials will illuminate and reshape the treatment paradigm
for symptomatic and asymptomatic carotid stenosis.
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angioplasty and stenting (CAS), and carotid endarterectomy
(CEA). The best medical management (BMM) of stroke entails
a combination antiplatelet therapy with aspirin and clopi-
dogrel, statin, antihypertensive agents, smoking cessation,
and possibly strict diabetic control and lifestyle changes. The
beneﬁts and progression of BMM have been extensively
reviewed elsewhere.7 This article is a perusal of the most
prominent randomized clinical trials (RCTs) examining dif-
ferent treatment modalities of carotid stenosis. It is also a
review of the latest literature published in the past 10 years
regarding the evolving techniques of CEA.
Symptomatic Carotid Stenosis
Two landmark studies have codiﬁed the management para-
digm of patients with symptomatic carotid stenosis. These
RCT enrolled patients with a recent stroke, reversible ische-
mic neurologic deﬁcit, transient ischemic attack (TIA), retinal
infarct or amaurosis fugax, and an ipsilateral carotid stenosis.
A considerable amount of time has elapsed since these trials,
and the control of these trials was treatment with aspirin,
which was considered the BMM at that time. Near occlusion
of internal carotid artery (ICA) deﬁned as 95% or greater in
North American Symptomatic Carotid Endarterectomy Trial
(NASCET) was excluded from this analysis of the NASCET and
European Carotid Surgery Trial (ECST) for the purpose of a
more equitable comparison8 (►Table 1).
It is important to be cognizant of the crucial differences
between NASCET and ECST, most notable of which is the
methodology of calculating the degree of stenosis. Both trials
used the residual luminal diameter of the narrowest part of
the ICA as the numerator, but the NASCET utilized the
diameter of the undiseased internal carotid as the denomi-
nator. ECSTon the contrary used the predicted outer diameter
of the ICA in the same diseased portion involving atheroscle-
rosis and stenosis. Additional studies demonstrated a linear
correlation between NASCET and ECST methods—50% steno-
sis in NASCET correlates with 65% stenosis in ECST; 70% in
NASCET corresponds to 82% in the ECST method.9,10 Another
salient point is, at the time of these trials, aspirin alone was
considered the best medical treatment, which, in the current
era, encompasses statin, aspirin, clopidogrel, and antihyper-
tensives, as mentioned previously. These discrepancies man-
date further investigation.
Asymptomatic Carotid Stenosis
About 3.5 to 5% of asymptomatic patients with stenosis
greater than 80% have a stroke each year.11 Although experts
agree that this is not a negligible rate, they disagree on the
optimal treatment method for asymptomatic patients. The
Asymptomatic Carotid Atherosclerosis (ACAS) and Asymp-
tomatic Carotid Stenosis Trial (ACST) comparing BMM and
CEA in asymptomatic patients suggested that an aggressive
intervention with CEA produces more advantageous out-
comes than BMM alone (►Table 2). The limitations of the
ACAS trial are using only aspirin as BMM and its subgroup
analysis that failed to demonstrate the beneﬁts of CEA in
women although this study was not powered to show gender
difference. The ACST utilized aspirin and antihypertensives
without statin, which also does notmeet the current standard
of care for medical treatment of carotid stenosis.
Carotid Angioplasty and Stenting versus
Carotid Endarterectomy
A prior study called the Carotid and Vertebral Artery Trans-
luminal Angioplasty Study (CAVATAS) compared endovascu-
lar treatment with CEA but used only balloon angioplasty
without stenting, which showed more frequent restenosis
with percutaneous intervention and demanded further in-
vestigations involving stenting.12 Two major RCTs shed light
on the comparative efﬁcacy of CEAversus CAS (►Table 3). The
SAPPHIRE trial was a small noninferiority trial that
Table 1 Major RCT’s comparing CEA versus BMM in symptomatic carotid stenosis8,56–60
Year, location Patients, n Inclusion criteria Absolute risk re-
duction of ipsilat-
eral stroke
Number needed
to treat
Critiques
NASCET 1998, Mostly
United States
and Canada
659 severe
stenosisa
858 moderate
stenosisa
Stenosis  30% Sever stenosis:
15% at 2 yb
Moderate stenosis:
6.5% at 5 y
6.7 for severe
15.4 for
moderate
Post-stenotic ICA
used in stenosis
degree calcula-
tion alters its
value
ECST 1998
14 European
countries
429 severe
stenosisa
646 moderate
stenosisa
Any degree of
stenosis
Severe stenosisc:
21.1% at 5 yb
Moderate stenosisc:
5.7% at 5 y
4.7 for severe
17.5 for
moderate
“Uncertainty
principle” lead-
ing to nebulous
inclusion and ex-
clusion criteria
Abbreviations: BMM, best medical management; CEA, carotid endarterectomy; ECST, The European Carotid Surgery Trial; ICA, internal carotid artery;
NASCET, The North American Symptomatic Carotid Endarterectomy Trial; RCT, randomized clinical trials.
aSevere stenosis > 70%, moderate stenosis between 50 and 69%.
bp < 0.05.
cDegree of stenosis was recalculated using the NASCET method.
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randomized patients with high surgical risks: severe cardiac
disease, severe pulmonary disease, contralateral carotid oc-
clusion, contralateral laryngeal-nerve palsy, restenosis after
prior CEA, previous radical neck surgery or radiation therapy
to the neck, and an age older than 80 years. Some notable
criticisms of the SAPPHIRE study are the sponsorship of the
trial and the involvement in the study design by the stent
company, Cordis, which inherently induces biases. The au-
thors of the SAPPHIRE trial also acknowledge that the trial
was not powered enough to render a deﬁnitive conclusion on
the beneﬁt of CAS or CEA in asymptomatic patients.13 Others
have noted ﬂaws in randomization because of the surgeons’
exclusion of high-risk patients at their discretion and their
relative inexperience in CEA.14
The CREST is a large RCT that generated many pivotal
questions. It was conducted by interventionalists and surgeons
chosen after a more robust credentialing process. It found CAS
equally effective as CEA in preventing ipsilateral stroke. The
initial conclusion was that both symptomatic and asymptom-
atic patients had no signiﬁcant discrepancy in stroke and death
rate after 4 years. The conclusions of the CREST have been
challenged after subgroup analyses. It has been criticized for
giving antiplatelets more aggressively with CAS.14 In symp-
tomatic patients, CAS had signiﬁcantly more stroke and death
as opposed to CEA (overall hazard ratio 1.9, perioperative
hazard ratio 1.89).15 Women16 also had signiﬁcantly more
stroke and death with CAS than with CEA (hazard ratio 1.35).
Furthermore, the efﬁcacyof CAS showed a negative correlation
with increasing age. CAS increased the stroke rate 1.77 times
for each 10-year interval in age.17 For ipsilateral stroke, CAS
patients older than 75 years have a hazard ratio of 2.17
periprocedurally and 2.15 at 4 years after the procedure.
Interestingly enough, this notion was not observed with CEA.
The SPACE trial is a noninferiority trial that enrolled only
the symptomatic patients with greater than 70% stenosis.
After 2 years of follow-up, the noninferiority was not proven.
The limitations of the SPACE trial are that CASwas performed
by interventionalists with as few as 10 prior procedures
under the guidance of a tutor and that the antiembolic device
was used in only 27% of CAS, making a fair comparison
difﬁcult.14 The trial was prematurely terminated because of
the funding issues and low conditional power.18
The EVA-3S is a French study that resulted in signiﬁcantly
higher incidents of ipsilateral stroke and deathwith CAS after
4 years is mostly accounted for by the 30-day perioperative
events and the risks equalize thereafter.19 This trial was also
prematurely terminated for safety and futility. Its authors
ascribed the risks with CAS to anatomical difﬁculties and the
interventionalists’ varying experience.20 A composite analy-
sis of three trials, EVA-3S, SPACE, and International Carotid
Stenting Study (ICSS) recommends CAS be performed by only
those who do more than six procedures per year.21
The ICSS is an RCT exploring similar questions. It needs a
long-term analysis but the 120-day analysis had more favor-
able results for CEA. As opposed to the other CAS trials, the
ICSSwas associated with higher myocardial infarction (MI) in
CAS instead of CEA. Another discrepancy in ICSS is prevent
cerebral ischemia in this study.22
Patch Carotid Endarterectomy versus
Primary Closure Carotid Endarterectomy
Recent literaturehas probed the different techniques of CEA. The
following threemajor techniquesprevail inCEA:primaryclosure
of endarterectomy, patch closure (pCEA), and eversion carotid
endarterectomy (eCEA). A recent abstract published in Stroke
Table 2 Major RCT’s comparing CEA versus BMM in asymptomatic carotid stenosis14,61,62
Year, location Patients, n Inclusion criteria Absolute risk
reduction of
stroke
Number needed
to treat
Critiques
ACAS61 1995, United
States, Canada
1,659 Stenosis  60% 5.9%a at 5 y 16.9 BMM included
only aspirin
No signiﬁcant
beneﬁt of CEA in
women
ACST62 2004, 30 European
countries
3,120 Stenosis  60% 5.4%a at 5 y for
< 75 y old
18.5 “Uncertainty
principle” lead-
ing to nebulous
inclusion and ex-
clusion criteria
BMM included
only aspirin and
antihyperten-
sives
Statins were
added later dur-
ing the trial
Abbreviations: ACAS, Asymptomatic Carotid Atherosclerosis; ACST, Asymptomatic Carotid Stenosis Trial; BMM, best medical management; CEA,
carotid endarterectomy; RCT, randomized clinical trials.
ap < 0.05.
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featured a subanalysis of the CREST, which was notable for a
signiﬁcant decrease in restenosis rates and perioperative stroke
rates with pCEA as opposed to primary closure.23 Numerous
previous studies have also shown superior results with pCEA
versus primary closure,24–28 but the optimal kind of the patch
remainsunclear. There are autografts using saphenousor jugular
Table 3 Major RCT’s comparing CAS and CEA13,18,19,63–67
Year, location Patients, n Inclusion criteria Results Comments,
critiques
Symptomatic and asymptomatic patients
SAPPHIRE 2008, United
States, Canada
237 Symptomatic:
stenosisa  50%
Asymptomatic:
Stenosisa  80%
High surgical risk
No signiﬁcant difference
in ipsilateral stroke
at 1 and 3 y
Embolism protective
device in CAS
Noninferiority
trial
No BMM control
group
Low conditional
power
CREST 2010, United
States
2,502 Symptomatic:
stenosisa  50%
on angio,
 70% on U/S,
CTA, and MRA
Asymptomatic:
Stenosisa  60% on
Angio,  70% on
U/S,  80% on
CTA and MRA
No signiﬁcant difference
in ipsilateral stroke
at 2.5 y and
estimated 4 y (HR, 1.1
with CAS)
Stroke risk 1.77 timesa
higher with CAS per
10 y after 75
No difference regarding
symptomatic status in
ipsilateral stroke or
death in 4 y
Sporadic use of
embolism protective
device in CAS
CAS received more
strict antiplatelet
control
Symptomatic patients only
SPACE 2006,
3 European countries
1,183 Stenosisb  70% Noninferiority could
not be validated
Restenosis  70%
greater in CASc at 2 y
Early termination:
low
conditional power,
funding issue
Embolic-protective
device used in
only 27%
Surgeons/
interventionalists
had as few as 10
procedures
Noninferiority study
EVA-3S 2006
France
527 Stenosisa  60%
(initially 70% but
expanded to include 60%)
Any stroke or death
higher with CASc at
30 d (RR, 2.5)
Ipsilateral stroke or
death higher with
CASc at 4 y (HR, 1.97)
Early termination
ICSS 2010
Europe
1,710 Stenosisa  50% Stroke, death, and
MI higher with
CASc at 120 d
(HR, 1.69)
Any stroke, all-cause
death higher with
CASc at 120 d
Needs a long-term
analysis
Abbreviations: Angio, angiography; BMM, best medical management; CREST, The Carotid Revascularization Endarterectomy versus Stenting Trial;
CAS, carotid angioplasty and stenting; CTA, CT angiogram; EVA-3S, Endarterectomy Versus Angioplasty in Patients with Symptomatic Severe Carotid
Stenosis; HR, hazard ratio; ICSS, International Carotid Stenting Study; MI, myocardial infarct; MRA, magnetic resonance angiogram; RR, relative risk;
SAPPHIRE, The Stenting and Angioplasty with Protection in Patients at High Risk for Endarterectomy; SPACE, Stent-Supported Percutaneous
Angioplasty of the Carotid Artery versus Endarterectomy; U/S, ultrasound.
aDegree of stenosis was recalculated using the NASCET method.
bDegree of stenosis was calculated using the ECST method.
cp < 0.05.
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vein, xenografts using bovine pericardium, as well as prosthetic
grafts using polytetraﬂuoroethylene (PTFE), polyester, or Da-
cron, none of which has deﬁnitively proven superiority over the
others. According to a systemic review of 13 RCTs, venous
autograft, PTFE, and Dacron all had equivalent perioperative
and long-term stroke, mortality, and restenosis rates.29 The
advantage of autogenous vein patches is that it is more consis-
tent with intima thickness which potentially translates to less
thrombosis.30 Yet, it is associated with increased risks of pseu-
doaneurysm formation31 and restenosis.32 Synthetic grafts are
more readily available, resistant to rupture, and foregoes the
opportunity cost of the lack of a vein graft for future coronary
bypass if need be.29 However, Dacron was linked to higher
infection rates and thrombogenicity,33 whereas achieving he-
mostasis wasmore difﬁcult when PTFEwas used.29When pCEA
using PTFE was compared with bovine pericardium pCEA, a
prospective randomized study resulted in comparable neuro-
logical events and death in both the groups.34
Eversion Carotid Endarterectomy versus
Prosthetic pCEA and Primary Closure
In a prospective but nonrandomized single-center study, eCEA
was associated with comparable rates of operative mortality
and postoperative TIA, stroke, and death to primary closure
and prosthetic pCEA using Dacron or PTFE.35 The study
suggested that eCEAmay be associatedwith a lower restenosis
rate presumably from postoperative hemodynamics that is
closer to the normal one. Other studies have hinted at the
potential of eCEA as an excellent alternative to pCEA.36,37
Discussion
Direct comparisons of these various studies have intrinsic
drawbacks. For example, primary end points were deﬁned
in slightly different ways among the different trials. These
studies had variegated methods of calculating the degree of
stenosis as noted earlier in comparing the NASCET and
ECST. They also used different imaging modalities. The
SAPPHIRE trial used carotid duplex to measure the degree
of stenosis, whereas the CREST used angiography, comput-
ed tomographic angiogram, magnetic resonance angio-
gram, as well as duplex, which may produce subtle yet
important differences because of the varying sensitivities
of these imaging modalities. Furthermore, there are differ-
ent types and companies for stents which may or may not
have used an embolic-protection device. Despite these, we
tried to analyze these studies using parallel and consistent
parameters for comparison, by using the recalculated ste-
notic degree according to the NASCET method when possi-
ble and especially focusing on ipsilateral stroke and death
rate as the primary end point.
Overwhelming evidence suggests CEA as the best treat-
ment for symptomatic patients. Both the NASCET and ECST
have set the treatment guidelines for symptomatic patients. A
meta-analysis of the NASCET, ECST, as well as the Veterans
Administration 309 Trial (VA309)38 rendered consistent re-
sults among the three and superiority of CEA to BMM of that
time which was aspirin alone.9
When CAS is juxtaposed to CEA, CAS has an inclination to
more frequent ipsilateral stroke and death in symptomatic
patients. CEA tended to havemoreMI, except in the ICSS trial.
Current literature lacks in the evidence for CEA versus BMM
comprised of the contemporary standard in both the symp-
tomatic and asymptomatic patients. The conjecture is that
CEA is better than even the most current standard of BMM as
well as CAS especially in symptomatic patients, and the
ongoing trials including ECST and CREST-2 will provide
more robust evidence. From a technical perspective, pCEA
appears as a sturdier repair than primary closure CEA, and
eCEA is a promising new technique that needs further
investigation.
In asymptomatic patients, the answer to the best treat-
ment is more nebulous. Although the ACAS and ACST have
demonstrated more advantageous outcomes with CEA versus
BMM in stenosis greater than 60%, these trials were antiquat-
ed in their deﬁnition of BMM. The utility of CAS in asymp-
tomatic patients is also questionable. CASwas associatedwith
signiﬁcantly higher periprocedural adverse events in many
trials. The subgroup analyses of the CREST showed a higher
stroke ratewith CAS thanwith CEA in asymptomatic patients.
The SAPPHIRE trial was not powered enough, and their
randomization was obscured by many factors. The noninfer-
iority premise of many of these studies is not strongly
substantiated, because many of these trials had design ﬂaws.
Moreover, the interventionalists’ and surgeons’ competency
and familiarity with the procedurewere often jeopardized by
their relative lack of experience.
Of note, age had a negative effect on the outcome of CAS.
The CREST demonstrated the inverse proportion between
increasing age and the outcomes of CAS, which incrementally
ampliﬁed the risks by 1.77 times for each 10 year increase in
Table 4 Currently ongoing trials
BMM CAS CEA
Asymptomatic ACST-2, ACT-1
SPACE-2 (3-armed)
Symptomatic and asymptomatic ECST-2, CREST-2 (2-armed)
Abbreviations: ACT-1, Asymptomatic Carotid Trial-1; ACST-2, Asymptomatic Carotid Surgery Trial-2; CREST-2, Carotid Revascularization Endarter-
ectomy versus Stenting Trial-2; ECST-2, European Carotid Surgery Trial-2; SPACE-2, Stent-protected angioplasty in asymptomatic carotid artery stenosis
vs. endarterectomy Trial-2.
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age. A meta-analysis of EVA-3S, SPACE, and ICSS found CAS
involving signiﬁcantly higher risks for stroke and death in
symptomatic patients older than 75 years.39 Gender is
another factor inﬂuencing the efﬁcacy of CAS. The post hoc
analysis of the CREST found female sex associated with
signiﬁcantly more frequent stroke, MI, and death when
treated with CAS versus CEA (hazard ratio 1.84,
p ¼ 0.047).16 The authors of the trial noted that this notion
was not observed in men and attributed this to women’s
increased embolic signals postoperatively,40,41 in addition to
impaired cerebrovascular reactivity.42,43 This trial was not
powered enough to delineate the interaction between symp-
tomatic status and gender.
Another potential disadvantage of CAS versus CEA is the
compromise of collateral blood supply. Although external
carotid artery (ECA) normally supplies structures external
to the brain, it can serve as a critical collateral supply to the
brain when ICA ﬂow is compromised.44,45 Several studies
have demonstrated a signiﬁcant increase in ECA occlusion46
and stenosis47–49 after CAS as opposed to CEA. Furthermore,
some studies have found more in-stent restenosis with ECA
stenosis after CAS.50,51 CAS can maximize its efﬁcacy in focal
restenosis after CEA52 and certain populations, such as youn-
ger men or patients with overwhelming cardiac risk or
previous neck irradiation.13,53
In light of these observations, asymptomatic patients may
be best treated with the most aggressive BMM rather than
CAS or CEA. Evidence demonstrates that asymptomatic pa-
tients have an acceptable annual stroke rate of 1.13%14,54
when treated with BMM. It behooves us to remember that
asymptomatic patients have a greater chance of cardiac
ischemia than a cerebral vascular accident.55 Current trials,
called “Trials 2,” will elucidate the best treatment paradigm
for asymptomatic carotid stenosis as well as a systemic
comparison of different treatment modalities (►Table 4).
Experts agree that even those patients who undergo CEA
should be maintained on the contemporary BMM regimen to
deter disease progression and to prevent secondary events.
Long-term follow-ups and continued evolution in risk strati-
ﬁcation in different patient populations with respect to age,
sex, and race will further enhance the outcomes of carotid
stenosis treatment.
Conclusion
Despite the lack of direct comparison between the contem-
porary modality of BMM alone and CEA with BMM in
symptomatic stenosis, there is a robust evidence for signiﬁ-
cant beneﬁt of CEA in symptomatic carotid stenosis with
severe stenosis and modest beneﬁt for moderate stenosis.
CAS faces questions about its efﬁcacy regarding age- and sex-
speciﬁc compromise. CAS can best serve focal restenosis after
CEA, younger men, and patients with overwhelming cardiac
risk or prior neck irradiation. Asymptomatic patients repre-
sent a treatment enigma at this point. While we await the
results from the ongoing trials, theymay bebest treated BMM
instead of more aggressive interventions.
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